The activity of the cancer-immune cycle comprehensively reflects the ultimate effect of the complex immunomodulatory interactions in TME.[44] In our study, we found that most of the immune step scores appeared to be upregulated in the SLC22A8 low expression group. Here, SLC22A8 is linked to cancer.